Maxygen, (FRA:MYN) Asset Impairment Charge : €0.00 Mil (TTM As of Mar. 2013)

View and export this data going back to . Start your Free Trial

What is Maxygen, Asset Impairment Charge?

Maxygen,'s Asset Impairment Charge for the three months ended in Mar. 2013 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2013 was €0.00 Mil.

Maxygen, Asset Impairment Charge Historical Data

The historical data trend for Maxygen,'s Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxygen, Asset Impairment Charge Chart

Maxygen, Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Asset Impairment Charge

Get a 7-Day Free Trial

Maxygen, Quarterly Data
	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Maxygen, Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Maxygen, Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Maxygen,'s Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxygen, (FRA:MYN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.